Skip to main content

Table 3 The association between oxygen therapy and all-cause in-hospital mortality in subgroup analysis

From: Is oxygen therapy beneficial for normoxemic patients with acute heart failure? A propensity score matched study

Characteristics

No. of total

No. Ambient Air

(No. of deaths)

No. Oxygen Therapy

(No. of deaths)

OR (95% CI)

P value

Duration of oxygen therapy (days)

  ≤ 3

741

–

741 (40)

0.87 (0.60–1.27)

0.472

 3–6

322

–

322 (28)

1.45 (0.94–2.25)

0.092

  > 6

167

–

167 (30)

3.34 (2.15–5.20)

<  0.001

Median SpO2 during treatment period (%)

 90–95

753

431 (33)

322 (26)

1.06 (0.62–1.81)

0.832

  > 95

2169

1261 (71)

908 (72)

1.44 (1.03–2.03)

0.034

Age (years)

  ≤ 72

1498

856 (41)

642 (38)

1.25 (0.79–1.97)

0.334

  > 72

1424

836 (63)

588 (60)

1.39 (0.96–2.02)

0.079

de novo AHF (n)

 Yes

1155

659 (58)

496 (58)

1.37 (0.92–2.22)

0.111

 No

1767

1033 (46)

734 (40)

1.24 (0.85–1.82)

0.258

AF (n)

 Yes

668

381 (28)

287 (34)

1.69 (1.00–2.87)

0.049

 No

2254

1311 (76)

943 (64)

1.18 (0.84–1.67)

0.337

MI (n)

 Yes

561

331 (33)

230 (22)

0.96 (0.54–1.69)

0.874

 No

2361

1361 (71)

1000 (76)

1.49 (1.07–2.09)

0.019

Stroke (n)

 Yes

301

178 (14)

123 (17)

1.88 (0.89–3.97)

0.099

 No

2621

1514 (90)

1107 (81)

1.25 (0.92–1.70)

0.161

Hypertension (n)

 Yes

1869

1041 (61)

828 (59)

1.23 (0.85–1.79)

0.268

 No

1053

651 (43)

402 (39)

1.52 (0.97–2.39)

0.070

CKD (n)

 Yes

775

451 (40)

324 (36)

1.28 (0.80–2.07)

0302

 No

2147

1241 (64)

906 (62)

1.35 (0.94–1.94)

0.102

RRT (n)

 Yes

149

102 (4)

47 (6)

3.59 (0.96–13.38)

0.057

 No

2773

1590 (100)

1183 (92)

1.26 (0.94–1.69)

0.128

  1. OR odds ratio, CI confidence interval, SpO2 pulse oximetry-derived oxygen saturation, AHF acute heart failure, AF atrial fibrillation, MI myocardial infarction, CKD chronic kidney disease, RRT renal replacement treatment, − no data